Understanding how HDAC3 affects Langerhans cell histiocytosis
Epigenetic Regulation of Langerhans Cell Histiocytosis Pathophysiology and Microenvironment by HDAC3
['FUNDING_FELLOWSHIP'] · WAYNE STATE UNIVERSITY · NIH-11030234
This study is looking at how a protein called HDAC3 affects Langerhans cell histiocytosis (LCH), a rare inflammatory condition, to find better and safer treatment options for patients like you.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WAYNE STATE UNIVERSITY (nih funded) |
| Locations | 1 site (DETROIT, UNITED STATES) |
| Trial ID | NIH-11030234 on ClinicalTrials.gov |
What this research studies
This research investigates the role of HDAC3 in the development and behavior of Langerhans cell histiocytosis (LCH), a rare inflammatory condition. By examining how HDAC3 influences myeloid cells, the study aims to uncover new therapeutic strategies that could improve treatment outcomes for patients with LCH. The approach involves analyzing the microenvironment of LCH and how it contributes to the disease's persistence and severity. Patients may benefit from insights that could lead to more effective and less toxic treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Langerhans cell histiocytosis, particularly those experiencing severe or recurrent forms of the disease.
Not a fit: Patients with other types of histiocytosis or those without a diagnosis of LCH may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve treatment outcomes for patients with LCH.
How similar studies have performed: While research on HDAC3 is ongoing, this specific approach to targeting LCH is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
DETROIT, UNITED STATES
- WAYNE STATE UNIVERSITY — DETROIT, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DIMITRION, PETER — WAYNE STATE UNIVERSITY
- Study coordinator: DIMITRION, PETER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.